** Shares of healthcare payments firm Waystar up 1.5% at $31.60
** Raymond James upgrades stock rating to "strong buy" from "outperform", maintains PT of $40
** The current valuation does not reflect the potential durability of double-digit growth amid broader secular shifts in healthcare to more modern technology - brokerage
** Growing healthcare complexity will only compound the regulatory and administrative burden on providers, which we think will disproportionally benefit vertical SaaS players with a suite sale - Raymond James
** Avg. rating of 10 brokerages for the stock is a "buy"; the median PT is $36, according to data compiled by LSEG
** As of last close, shares up 44.8% from WAY's June IPO price of $21.50
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。